| Autor: |
Bandini, M. Pederzoli, F. Madison, R. Briganti, A. Ross, J.S. Niegisch, G. Yu, E.Y. Bamias, A. Agarwal, N. Sridhar, S.S. Rosenberg, J.E. Bellmunt, J. Pal, S.K. Galsky, M.D. Lucianò, R. Gallina, A. Salonia, A. Montorsi, F. Ali, S.M. Chung, J.H. Necchi, A. |
| Jazyk: |
angličtina |
| Rok vydání: |
2020 |
| Popis: |
Background: Nonurothelial carcinoma (UC) malignancies have traditionally been considered to have a more aggressive clinical course, and little is known about their response to neoadjuvant therapy. We examined the effect of neoadjuvant chemotherapy (NAC) on a large population of patients with bladder cancer (BCa) with different histologic variants (HVs). Patients and Methods: We relied on a retrospective, multicenter database of 2858 patients with BCa who had undergone radical cystectomy with or without NAC from 1990 to 2017. Pure and mixed HVs were grouped into 6 categories: squamous cell carcinoma (SCC; n = 283; 45%), other subtypes (n = 95; 15%), micropapillary (n = 85; 14%), adenocarcinoma (n = 65; 10%), small cell (n = 54; 8.6%), and sarcomatous (n = 47; 7.6%). Kaplan-Meier and Cox regression analyses were used to examine cancer-specific survival (CSS) according to the HV, using pure UC as the reference. Logistic regression models were used to examine the odds of clinical-to-pathologic downstaging after NAC according to the HV. Results: Overall, we identified 2229 cases of pure UC and 629 cases of BCa with HVs at radical cystectomy. Of the 450 NAC-treated patients, only those patients with SCC (n = 44; 9.8%) had had worse CSS (median CSS, 33 vs. 116 months; P |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
